Certior Financial Group LLC Makes New $421,000 Investment in Pfizer Inc. (NYSE:PFE)

Certior Financial Group LLC bought a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 15,863 shares of the biopharmaceutical company’s stock, valued at approximately $421,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer in the 4th quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new position in Pfizer during the fourth quarter worth $31,000. Finally, Curio Wealth LLC purchased a new position in Pfizer in the fourth quarter worth $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 5.4 %

Shares of NYSE:PFE opened at $22.99 on Monday. The company has a market capitalization of $130.39 billion, a price-to-earnings ratio of 16.31, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a 50 day moving average of $25.87 and a two-hundred day moving average of $26.72. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52-week low of $22.28 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, UBS Group dropped their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.